Gilead Sciences
-
Gilead expands global Lenacapavir reach through strategic PAHO partnership
The partnership complements existing mechanisms for supplying generic versions of lenacapavir and aims to address gaps in HIV prevention across the region.
-
Gilead Sciences opens new research centre in California to accelerate drug discovery
It will house about 325 employees, including 260 laboratory scientists, and provide adaptable laboratories, collaborative workspaces and shared technology platforms.
-
Gilead, Merck present pivotal Phase 3 Islend data for first once-weekly oral HIV regimen
Researchers presented the findings at the 26th International AIDS Conference in Rio de Janeiro, Brazil.
-
Gilead Sciences completes US$5B Tubulis acquisition to strengthen ADC oncology pipeline
The acquisition provides Gilead access to Tubulis’ proprietary ADC platforms designed to improve selective tumour targeting and payload delivery.
-
WHO renews five-year partnership with Gilead Sciences to eliminate deadly Kala-Azar disease
Since the partnership began, Gilead has supplied more than 1.1 million vials of AmBisome and contributed over US$18 million in funding.
-
Gilead Sciences expands API supply partnership with Yuhan in US$140M deal through 2027
Yuhan operates two API manufacturing facilities in South Korea and has reported steady international growth, with overseas sales increasing 21% in the first quarter.
-
Gilead pays USD45M to secure Kymera’s unique CDK2 molecular glue for cancer
Through this agreement, Gilead now controls global rights to KT-200, an oral CDK2 molecular glue degrader designed to treat cancer.
-
Gilead acquires German biotech Tubulis for USD5B in major push into cancer drug development
The two companies began collaborating in 2024 through an option and license agreement valued at up to USD 465 million, which granted Gilead access to Tubulis’ proprietary ADC platforms.
-
Gilead Sciences invests USD2.2 billion in T-Cell Engager Technology through Ouro Medicines acquisition
Gilead will pay USD1.68 billion upfront and commit up to USD500 million in milestone payments to secure gamgertamig (OM336), Ouro’s BCMA/CD3-targeting TCE.
-
Gilead Sciences buys Arcellx for USD7.8B to strengthen its CAR-T cancer treatment portfolio
The acquisition centers on anitocabtagene autoleucel, known as anito-cel, an investigational CAR-T cell therapy targeting multiple myeloma.